Dr. Han Phan, MD
NPI: 1306954037
Total Payments
$274,690
2024 Payments
$16,128
Companies
11
Transactions
75
Payment Breakdown by Category
Research$224,719 (81.8%)
Consulting$44,055 (16.0%)
Travel$4,310 (1.6%)
Food & Beverage$1,509 (0.5%)
Education$96.50 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $224,719 | 22 | 81.8% |
| Consulting Fee | $44,055 | 9 | 16.0% |
| Travel and Lodging | $4,310 | 14 | 1.6% |
| Food and Beverage | $1,509 | 28 | 0.5% |
| Education | $96.50 | 2 | 0.0% |
Payments by Type
Research
$224,719
22 transactions
General
$49,970
53 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $200,559 | 12 | $0 (2023) |
| Sarepta Therapeutics, Inc. | $31,371 | 32 | $0 (2024) |
| PFIZER INC. | $16,707 | 7 | $0 (2024) |
| Eli Lilly and Company | $13,952 | 4 | $0 (2024) |
| Genentech USA, Inc. | $7,315 | 3 | $0 (2023) |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $3,164 | 1 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,256 | 12 | $0 (2019) |
| Genentech, Inc. | $132.07 | 1 | $0 (2022) |
| NS Pharma, Inc. | $109.99 | 1 | $0 (2024) |
| GENZYME CORPORATION | $81.84 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,128 | 8 | Eli Lilly and Company ($12,716) |
| 2023 | $20,193 | 15 | PFIZER INC. ($16,673) |
| 2022 | $23,194 | 18 | Sarepta Therapeutics, Inc. ($20,994) |
| 2021 | $13,332 | 10 | Sarepta Therapeutics, Inc. ($10,082) |
| 2020 | $1,200 | 1 | Biogen, Inc. ($1,200) |
| 2019 | $4,968 | 14 | Biogen, Inc. ($3,712) |
| 2018 | $195,448 | 6 | Biogen, Inc. ($195,448) |
| 2017 | $227.14 | 3 | Sarepta Therapeutics, Inc. ($122.36) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Insmed, Inc. | — | Food and Beverage | In-kind items and services | $42.25 | General |
| 09/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $6,358.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | ||||||
| 09/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $6,358.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | ||||||
| 08/01/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Food and Beverage | In-kind items and services | $34.97 | General |
| Category: Genetic Disease | ||||||
| 04/24/2024 | NS Pharma, Inc. | VILTEPSO (Drug) | Food and Beverage | In-kind items and services | $109.99 | General |
| Category: PEDIATRIC NEUROLOGY | ||||||
| 04/10/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $33.47 | General |
| 03/26/2024 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | ZOLGENSMA (Drug) | — | Cash or cash equivalent | $3,164.42 | Research |
| Study: Research Medical Writing and Publication Support • Category: Neurology | ||||||
| 02/06/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: Genetic Disease | ||||||
| 12/07/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,235.47 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 12/04/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $23.32 | General |
| 10/20/2023 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $21.42 | General |
| 10/05/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,543.86 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 08/21/2023 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.04 | General |
| 08/17/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $10,378.49 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 08/05/2023 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Genetic Disease | ||||||
| 08/03/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $20.95 | General |
| 06/27/2023 | Eli Lilly and Company | — | — | In-kind items and services | $764.68 | Research |
| Study: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | ||||||
| 06/21/2023 | Eli Lilly and Company | — | — | In-kind items and services | $470.96 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | ||||||
| 05/18/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,470.94 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 03/29/2023 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $20.66 | General |
| 03/28/2023 | Genentech USA, Inc. | Evrysdi (Drug) | Consulting Fee | Cash or cash equivalent | $2,070.00 | General |
| Category: Neurology | ||||||
| 03/20/2023 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | In-kind items and services | $102.79 | General |
| Category: Neurology | ||||||
| 03/06/2023 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.78 | General |
| 10/22/2022 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,200.00 | General |
| 10/22/2022 | Sarepta Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $672.21 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Pilot Newborn Screening Study for Spinal Muscular Atrophy in the State of Georgia | Biogen, Inc. | $189,719 | 1 |
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $16,629 | 4 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | Eli Lilly and Company | $6,358 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | Eli Lilly and Company | $6,358 | 1 |
| Research Medical Writing and Publication Support | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $3,164 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents | Teva Pharmaceuticals USA, Inc. | $1,256 | 12 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | Eli Lilly and Company | $764.68 | 1 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | Eli Lilly and Company | $470.96 | 1 |
About Dr. Han Phan, MD
Dr. Han Phan, MD is a Neurology with Special Qualifications in Child Neurology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306954037.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Han Phan, MD has received a total of $274,690 in payments from pharmaceutical and medical device companies, with $16,128 received in 2024. These payments were reported across 75 transactions from 11 companies. The most common payment nature is "" ($224,719).
Ad
Practice Information
- Specialty Neurology with Special Qualifications in Child Neurology
- Location Atlanta, GA
- Active Since 08/25/2006
- Last Updated 05/27/2009
- Taxonomy Code 2084N0402X
- Entity Type Individual
- NPI Number 1306954037
Products in Payments
- NURTEC ODT (Drug) $16,629
- SPINRAZA (Biological) $10,727
- Evrysdi (Drug) $7,447
- ZOLGENSMA (Drug) $3,164
- Austedo (Drug) $680.85
- AUSTEDO (Drug) $574.85
- EXONDYS 51 (Drug) $122.36
- VILTEPSO (Drug) $109.99
- POMPE - DISEASE (Drug) $81.84
- Elevidys (Drug) $80.29
- Exondys 51 (Drug) $13.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology with Special Qualifications in Child Neurology Doctors in Atlanta
Dr. Chaouki Khoury, Md, Ms, MD, MS
Neurology with Special Qualifications in Child Neurology — Payments: $733,835
Neurology with Special Qualifications in Child Neurology $733,835
Raymond Cheng, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $96,624
Neurology with Special Qualifications in Child Neurology $96,624
Howard Schub, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $11,014
Neurology with Special Qualifications in Child Neurology $11,014
Dr. Cherise Frazier, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $7,721
Neurology with Special Qualifications in Child Neurology $7,721
Ton De Grauw, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $7,657
Neurology with Special Qualifications in Child Neurology $7,657
Sumit Verma, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $4,297
Neurology with Special Qualifications in Child Neurology $4,297